Group 1 - The blood oxygen monitor concept sector rose by 5.65%, ranking third among concept sectors, with 24 stocks increasing, including Aipeng Medical and Lepu Medical reaching a 20% limit up [1] - The top gainers in the blood oxygen monitor sector included Jiahe Intelligent, Kefu Medical, and Libang Instruments, which rose by 13.18%, 11.10%, and 7.82% respectively [1] - The blood oxygen monitor sector saw a net inflow of 943 million yuan from main funds, with 15 stocks receiving net inflows, and 7 stocks exceeding 10 million yuan in net inflow [1] Group 2 - The leading stocks in terms of net inflow ratio included Aipeng Medical, Lepu Medical, and Hongri Pharmaceutical, with net inflow ratios of 25.43%, 18.55%, and 14.65% respectively [2] - The top stocks by main fund flow in the blood oxygen monitor sector included Lepu Medical with a net inflow of 485 million yuan, followed by Sichuan Changhong and Aipeng Medical with net inflows of 195 million yuan and 156 million yuan respectively [2] - The trading performance of various stocks showed significant fluctuations, with some stocks like Aipeng Medical and Lepu Medical achieving notable gains and high turnover rates [3]

Group 1 - The company is progressing as planned with its "X-ray vacuum device and comprehensive solution construction project" and is advancing the R&D and customer introduction of key products [2] - The company has completed the R&D of several types of tubes including micro-focus tubes, transmission target tubes, dental tubes, DR tubes, C-arm tubes, and some CT tubes [2] - Micro-focus tubes, transmission target tubes, dental intraoral tubes, and CBCT tubes have already entered mass production, while the C-arm tubes have completed registration and are transitioning to production [2] Group 2 - Some DR tubes and CT tubes are expected to start registration in the first quarter of 2026 [2] - As the company’s tube products gradually complete registration and commercialization, along with the expansion of its comprehensive solution business, it is anticipated that future orders and self-use quantities will gradually increase [2]

（记者 曾健辉） 每经AI快讯，普门科技1月5日晚间发布公告称，深圳普门科技股份有限公司于近期收到了1个国家药品 监督管理局颁发的《中华人民共和国医疗器械注册证》。产品名称为"肿瘤标志物质控品"。 每经头条（nbdtoutiao）——秒光！1499元飞天茅台上线即空，i茅台App冲上苹果购物榜第一，10万用 户已下单！经销商同价做回馈，1000箱很快卖完 ...

（记者 贾运可） 每经AI快讯，三诺生物1月5日晚间发布公告称，截至2025年12月31日，公司通过股份回购专用证券账 户以集中竞价交易方式累计回购公司股份约1031万股，占公司当前总股本的比例为1.84%，本次回购股 份的最高成交价为21.39元/股，最低成交价为17.27元/股，成交总金额约为2.02亿元。 每经头条（nbdtoutiao）——秒光！1499元飞天茅台上线即空，i茅台App冲上苹果购物榜第一，10万用 户已下单！经销商同价做回馈，1000箱很快卖完 ...

证券之星消息，1月5日医疗器械板块较上一交易日上涨5.5%，锦好医疗领涨。当日上证指数报收于 4023.42，上涨1.38%。深证成指报收于13828.63，上涨2.24%。医疗器械板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 920925 | 锦好医疗 | 38.23 | 20.03% | 10.83万 | | 3.94亿 | | 688767 | 博拓生物 | 45.34 | 20.01% | 15.96万 | | 7.08亿 | | 688108 | 赛诺医疗 | 23.09 | 20.01% | 61.92万 | | 13.72亿 | | 300238 | 冠昊生物 | 16.62 | 20.00% | - 36.46万 | | 5.75亿 | | 300753 | 爰朋医疗 | 33.30 | 20.00% | 18.79万 | | 6.15亿 | | 301363 | 美好医疗 | 28.86 | 20.00% | 7.38万 | | 2.13 ...

Core Viewpoint - Tianchen Medical (688013.SH) has signed a strategic cooperation agreement with Inspur Digital Technology (Shanghai) Co., Ltd. to promote innovation and industrialization in medical intelligent manufacturing and robotics by December 31, 2025 [1] Group 1: Strategic Cooperation - The agreement aims to advance the intelligent manufacturing of medical devices and consumables, as well as the research and production of medical robots [1] - This strategic partnership is a significant step in implementing the company's dual-engine strategy, which focuses on minimally invasive capabilities driven by end-execution components and an intelligent ecosystem for surgical robots supported by the MA platform [1] - The signing of the agreement establishes a long-term cooperative relationship and provides a framework for future project collaborations, facilitating industrial integration and mutual benefits for both parties [1]

天臣医疗(688013.SH)公告，公司(乙方)与浪潮数字科技(上海)有限公司(简称"浪潮数科"、甲方)于2025 年12月31日签署了《战略合作协议》。双方拟共同推动医疗智能化、信息化技术在医疗器械设备与耗材 的智能化制造、医疗机器人研发生产等领域的创新应用与产业化落地。 ...

Core Viewpoint - The A-share market experienced a strong opening on January 5, 2026, with all three major indices rising significantly, marking a notable recovery and investor enthusiasm in the market [1][3]. Market Performance - The Shanghai Composite Index rose by 1.38% to close at 4023.42 points, achieving a "12 consecutive days of gains," the longest streak in over 30 years [3]. - The Shenzhen Component Index and the ChiNext Index increased by 2.24% and 2.85%, closing at 13828.63 points and 3294.55 points, respectively [3]. - The STAR 50 Index performed exceptionally well, rising by 4.4% to 1403.41 points [3]. Sector Performance - The brain engineering sector led the gains, with several stocks hitting the daily limit of 20% increase, including Sanbo Brain Science and Botao Biology [3]. - The insurance sector was active, with all major stocks in the sector showing positive performance [3]. - Other sectors with notable gains included fourth-generation semiconductors, medical devices, and AI pharmaceuticals [3]. Trading Volume - The total trading volume on January 5 was approximately 2.55 trillion yuan, with the Shanghai Stock Exchange contributing 1.067 trillion yuan and the Shenzhen Stock Exchange 1.479 trillion yuan [3]. - The Beijing Stock Exchange recorded a trading volume of 21.14 billion yuan [3]. Individual Stock Performance - China Satellite topped the individual stock trading volume with 19.454 billion yuan, followed closely by Sanhua Intelligent Control at 19.212 billion yuan [4]. - A total of 4185 stocks rose, with 127 stocks hitting the daily limit, indicating a strong profit-making environment for investors [5]. Market Outlook - According to a report from招商证券, A-share market is expected to see a continued net inflow of funds, potentially reaching 1.56 trillion yuan, supporting a slow bull market [5]. - The core logic supporting the current bull market remains unchanged, including ongoing policy support, a significant shift in household savings, and continuous breakthroughs in technological innovation [5]. - The current bull market is characterized as a slow and long-term trend, potentially lasting 3 to 10 years, marking a golden investment period for the Chinese capital market [5].

智通财经APP讯，天臣医疗(688013.SH)公告，公司(乙方)与浪潮数字科技(上海)有限公司(简称"浪潮数 科"、甲方)于2025年12月31日签署了《战略合作协议》。双方拟共同推动医疗智能化、信息化技术在医 疗器械设备与耗材的智能化制造、医疗机器人研发生产等领域的创新应用与产业化落地。 ...

智通财经APP讯，科华生物(002022.SZ)公告，公司收到国家药品监督管理局颁发的医疗器械注册证(体 外诊断试剂)，产品名称为：甲型肝炎病毒IgM抗体检测试剂盒(化学发光法)。 ...